Madrigal (MDGL) Q1 2026 Earnings Transcript

Madrigal reported first-quarter 2026 net sales of $311.3 million, up 127% year over year, with Rezdiffra active patients rising to more than 42,250 and trailing 12-month sales topping $1.1 billion. Management said the MASH market has expanded nearly 50% in two years, gross-to-net discounts are now expected in the mid- to high-30% range, and the company remains well funded with $817.9 million in cash. The company also expanded its pipeline with ARO-PNPLA3 and reaffirmed 2027/2028 data catalysts, though it does not expect profitability in 2026.

Analysis

MDGL is transitioning from a single-asset launch story into a platform compounding story, and that matters more than the headline growth rate. The key second-order effect is that commercial success is now funding a broader data flywheel: more prescribers, more real-world evidence, and better payer leverage, which should lower future adoption friction even if competition broadens the category. That creates a classic “winner expands the market” dynamic where competitive launches can actually validate the category and accelerate MDGL’s penetration before any rival has enough scale to matter.

The near-term debate is not demand; it is durability of the growth slope versus expense intensity. Gross-to-net has likely become a little less scary than investors modeled, but SG&A is still the swing factor because management is choosing to buy share now and defer profitability. The market should view that as rational if patient adds keep compounding, but it also means the stock is implicitly pricing a long runway in which commercial execution must outrun spending for multiple quarters, not just one.

The bigger contrarian setup is that the real upside may come from indication expansion and combination optionality rather than the current F2/F3 base. If the cirrhosis program de-risks in 2027, the addressable market re-rates materially because it changes Rezdiffra from best-in-class launch to a broader chronic liver franchise. The risk is that the pipeline gets valued as free optionality today; if later biomarker or outcomes data disappoint, MDGL could give back a lot of the multiple expansion even while the base business remains strong. That makes this a quality-growth name with a binary-long-dated catalyst stack, not a clean straight-line compounding story.

Key Decisions for Investors

• Long MDGL into the next 3-6 months on a pullback, with the thesis that the market is still underestimating commercial durability; risk/reward skews 2:1 if patient adds continue compounding and gross-to-net stabilizes in the mid/high-30s.
• Buy MDGL Jan-2027 calls or call spreads to express upside into the 2027 cirrhosis readout; this captures the highest-conviction catalyst while limiting downside to premium if the event-rate thesis breaks.
• Pair trade: long MDGL / short a basket of MASH laggards or recent entrants with no approved product, to isolate franchise-quality and first-mover advantage rather than category beta.
• If already long, hedge into the 2026 SG&A step-up with a tight trailing stop or partial trim after strength; the market may overreact to quarterly margin noise before the 2027 data path matters.
• Avoid shorting MDGL outright on the launch numbers alone; the better short expression is a future spread trade against any MASH competitor that depends on category growth but lacks MDGL’s prescriber moat and commercial infrastructure.